Loading...
Antitumour Imidazotetrazines: Past, Present... and Future?
Stevens, M.F.G. Wheelhouse, Richard T.
Stevens, M.F.G.
Wheelhouse, Richard T.
Publication Date
2023
End of Embargo
Supervisor
Keywords
Rights
© 2023 The Author(s). This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2023-08-18
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide
and mitozolomide to the world and 30 since the discovery that they function as prodrugs
of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the
first-line treatment for glioma but despite the attentions of the inventors and others, further examples of
this intriguing ring system have yet to enter the clinic.
Version
Published version
Citation
Stevens MFG and Wheelhouse RT (2023) Antitumour Imidazotetrazines: Past, Present... and Future?. RSC Chemical Biology. 4(10): 736-741.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article